Comparison of patients with or without hemorrhagic transformation in the active cancer group
| Hemorrhagic transformation | Yes | No | P value |
| N=11 | N=8 | ||
| Location/type of primary tumor, n (%) | 0.75 | ||
| Breast cancer | 2 (18) | 1 (12.5) | |
| Gastrointestinal | 1 (9) | 1 (12.5) | |
| Hematological | 2 (18) | 0 | |
| Hepatobiliary | 1 (9) | 0 | |
| Lung adenocarcinoma | 2 (18) | 3 (37.5) | |
| Prostate cancer | 1 (9.1) | 0 | |
| Urogenital | 1 (9) | 3 (37.5) | |
| Small cell carcinoma of the lung | 1 (9) | 0 | |
| Stage of primary tumor, n (%) | 1 | ||
| I | 1 (12.5) | 0 | |
| II | 2 (25.0) | 1 (12.5) | |
| III | 3 (37.5) | 3 (37.5) | |
| IV | 2 (25.0) | 4 (50.0) | |
| Missing | 3 | 0 | |
| Anticoagulants—yes, n (%) | 2 (20) | 3 (37.5) | 0.61 |
| Missing | 1 | ||
| Last known well (hours), mean±SD | 4.50±1.48 | 3.96±1.7 | 0 |
| ASPECTS, median (IQR) | 7.5 (2.8) | 8 (2.3) | |
| Missing | 1 | ||
| IV-tPA, n (%) | 7 (63.6) | 1 (12.5) | 0 |
ASPECTS, Alberta Stroke Program Early CT Score; IV-tPA, intravenous tissue plasminogen activator.